ECSP066355A - Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 - Google Patents

Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2

Info

Publication number
ECSP066355A
ECSP066355A EC2006006355A ECSP066355A ECSP066355A EC SP066355 A ECSP066355 A EC SP066355A EC 2006006355 A EC2006006355 A EC 2006006355A EC SP066355 A ECSP066355 A EC SP066355A EC SP066355 A ECSP066355 A EC SP066355A
Authority
EC
Ecuador
Prior art keywords
modulators
compounds
ilsulphonylamine
colecistocinine
quinoxalin
Prior art date
Application number
EC2006006355A
Other languages
English (en)
Inventor
Brett D Allison
Victor K Phuong
Michael H Rabinowitz
Michael D Hack
Mark D Rosen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP066355A publication Critical patent/ECSP066355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ciertos compuesto de amidofenil-sulfonilamino-quinoxalina son moduladores de la CCK2 útiles en el tratamiento de las enfermedades mediadas por la CCK2.
EC2006006355A 2003-08-08 2006-02-08 Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2 ECSP066355A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
ECSP066355A true ECSP066355A (es) 2006-08-30

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006355A ECSP066355A (es) 2003-08-08 2006-02-08 Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2

Country Status (33)

Country Link
US (3) US7304051B2 (es)
EP (2) EP1651622B1 (es)
JP (2) JP2007501842A (es)
KR (1) KR20060060007A (es)
CN (2) CN1863782A (es)
AR (1) AR045930A1 (es)
AT (2) ATE353322T1 (es)
AU (2) AU2004265312B2 (es)
BR (1) BRPI0413449A (es)
CA (2) CA2534887A1 (es)
CR (1) CR8229A (es)
CY (1) CY1106486T1 (es)
DE (2) DE602004015614D1 (es)
DK (2) DK1651622T3 (es)
EA (1) EA200600203A1 (es)
EC (1) ECSP066355A (es)
ES (2) ES2281834T3 (es)
HR (1) HRP20080559T3 (es)
IL (1) IL173591A0 (es)
IS (1) IS8280A (es)
LT (1) LT5410B (es)
LV (1) LV13453B (es)
MX (2) MXPA06001482A (es)
NO (1) NO20061122L (es)
NZ (1) NZ545030A (es)
PL (2) PL1651621T3 (es)
PT (2) PT1651621E (es)
SG (1) SG131114A1 (es)
SI (2) SI1651621T1 (es)
TW (1) TW200521120A (es)
UA (1) UA84025C2 (es)
WO (2) WO2005016896A1 (es)
ZA (1) ZA200601946B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1651621E (pt) * 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131243B1 (en) * 2008-06-02 2015-07-01 ASML Netherlands B.V. Lithographic apparatus and method for calibrating a stage position
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
US9115132B2 (en) 2010-07-09 2015-08-25 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
EP2705035B1 (en) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
BR112014017780A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
PL2820010T3 (pl) 2012-03-01 2018-11-30 Allergan, Inc. Pochodne benzofurano-2-sulfonamidu jako modulatory receptora chemokinowego
KR20150079951A (ko) 2012-11-05 2015-07-08 자프겐 인크. 간 질환의 치료 방법
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
PL3071206T3 (pl) 2013-11-22 2022-01-17 CL BioSciences LLC Antagoniści gastryny (eg yf476, netazepid) do leczenia i zapobiegania osteoporozie
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
ES2152989T3 (es) * 1993-08-10 2001-02-16 Black James Foundation Ligandos para los receptores de gastrina y cck.
DE69724644D1 (de) 1996-12-10 2003-10-09 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) * 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
PT1651621E (pt) * 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
CN101061116A (zh) * 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物

Also Published As

Publication number Publication date
DK1651621T3 (da) 2008-11-10
PT1651621E (pt) 2008-09-30
CN1863782A (zh) 2006-11-15
JP2007501841A (ja) 2007-02-01
CN1863781A (zh) 2006-11-15
HRP20080559T3 (en) 2009-01-31
BRPI0413449A (pt) 2006-10-17
DE602004004663D1 (de) 2007-03-22
CA2534887A1 (en) 2005-02-24
EP1651621B1 (en) 2008-08-06
US20080076918A1 (en) 2008-03-27
US20050038032A1 (en) 2005-02-17
NO20061122L (no) 2006-05-04
WO2005016896A1 (en) 2005-02-24
LT2006017A (en) 2006-11-27
NZ545030A (en) 2009-08-28
UA84025C2 (en) 2008-09-10
AU2004265311A1 (en) 2005-02-24
CA2534885C (en) 2013-06-04
KR20060060007A (ko) 2006-06-02
EA200600203A1 (ru) 2006-08-25
ATE403650T1 (de) 2008-08-15
MXPA06001550A (es) 2006-09-04
CA2534885A1 (en) 2005-02-24
JP4818110B2 (ja) 2011-11-16
US7563895B2 (en) 2009-07-21
AU2004265312B2 (en) 2010-05-20
CR8229A (es) 2008-09-10
PT1651622E (pt) 2007-04-30
LT5410B (lt) 2007-03-26
PL1651621T3 (pl) 2009-01-30
DE602004015614D1 (de) 2008-09-18
US7304051B2 (en) 2007-12-04
AR045930A1 (es) 2005-11-16
EP1651621A1 (en) 2006-05-03
EP1651622B1 (en) 2007-02-07
IL173591A0 (en) 2006-07-05
ATE353322T1 (de) 2007-02-15
JP2007501842A (ja) 2007-02-01
AU2004265312A1 (en) 2005-02-24
PL1651622T3 (pl) 2007-07-31
CY1106486T1 (el) 2012-01-25
US20050043310A1 (en) 2005-02-24
ES2281834T3 (es) 2007-10-01
SI1651621T1 (sl) 2008-12-31
EP1651622A1 (en) 2006-05-03
ZA200601946B (en) 2007-05-30
US7288651B2 (en) 2007-10-30
WO2005016897A1 (en) 2005-02-24
DK1651622T3 (da) 2007-05-07
ES2310294T3 (es) 2009-01-01
LV13453B (en) 2007-02-20
DE602004004663T2 (de) 2007-11-22
MXPA06001482A (es) 2006-09-04
TW200521120A (en) 2005-07-01
IS8280A (is) 2006-01-31
SG131114A1 (en) 2007-04-26
SI1651622T1 (sl) 2007-06-30

Similar Documents

Publication Publication Date Title
ECSP066355A (es) Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2
ECSP077360A (es) Compuestos sulfonamida
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
ATE461217T1 (de) Glp-1-verbindungen
DE602004028359D1 (de) Reinigung von biologisch produziertem 1,3-propandiol
NI200600094A (es) Compuesto heterociclicos fusionados
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
AR091405A2 (es) Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
TW200509892A (en) Novel aminobenzophenone compounds
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
ECSP056064A (es) Compuestos de benzopirano utiles para tratar estados inflamatorios
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
EA200501222A1 (ru) Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
BRPI0818581A2 (pt) Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
DE602005012993D1 (de) Einheit zur behandlung von pellets
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
DE50310579D1 (de) Furancarboxamide
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
DE50303586D1 (de) Methylthiophencarboxanilide
UY28145A1 (es) Nuevos compuestos farmaceuticos
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
UY26997A1 (es) Alquinilamidas y aplicaciones terapéuticas de las mismas